Tianjin Lisheng Pharmaceutical Co Ltd (002393) — Free Cash Flow Generation Index
Tianjin Lisheng Pharmaceutical Co Ltd (002393) has a Free Cash Flow Generation Index of 0.93x as of December 2025. Free cash flow of CN¥267.70 Million represents 1% of operating cash flow (CN¥287.81 Million). Read Tianjin Lisheng Pharmaceutical Co Ltd total liabilities for a breakdown of total debt and financial obligations.
FCF Generation Index
Free Cash Flow
Operating Cash Flow
Capital Expenditures
Tianjin Lisheng Pharmaceutical Co Ltd Free Cash Flow Generation Index (2007–2025)
Historical FCF Generation Index trend for Tianjin Lisheng Pharmaceutical Co Ltd across 19 annual periods. Explore Tianjin Lisheng Pharmaceutical Co Ltd (002393) reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
Annual Free Cash Flow Generation for Tianjin Lisheng Pharmaceutical Co Ltd (2007–2025)
Year-by-year Free Cash Flow Generation Index for Tianjin Lisheng Pharmaceutical Co Ltd. For the full company profile including market capitalisation, see 002393 market cap overview.
| Year | FCG Index | Free Cash Flow (CNY) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.92x | CN¥414.39 Million | CN¥451.85 Million | CN¥37.46 Million | ▲ +134.5% |
| 2024 | 0.39x | CN¥34.51 Million | CN¥88.26 Million | CN¥53.75 Million | ▼ -40.8% |
| 2023 | 0.66x | CN¥138.29 Million | CN¥209.51 Million | CN¥61.72 Million | ▼ -24.7% |
| 2022 | 0.88x | CN¥290.47 Million | CN¥331.38 Million | CN¥40.91 Million | ▲ +59.2% |
| 2021 | 0.55x | CN¥108.10 Million | CN¥196.34 Million | CN¥88.24 Million | ▲ +273.1% |
| 2020 | -0.32x | CN¥-24.29 Million | CN¥76.37 Million | CN¥100.66 Million | ▼ -148.0% |
| 2019 | 0.66x | CN¥177.87 Million | CN¥268.33 Million | CN¥90.46 Million | ▲ +85.1% |
| 2018 | 0.36x | CN¥58.26 Million | CN¥162.69 Million | CN¥104.43 Million | ▼ -50.3% |
| 2017 | 0.72x | CN¥129.16 Million | CN¥179.25 Million | CN¥50.09 Million | ▲ +243.7% |
| 2016 | 0.21x | CN¥36.40 Million | CN¥173.60 Million | CN¥137.20 Million | ▲ +741.7% |
| 2015 | -0.03x | CN¥-6.47 Million | CN¥198.13 Million | CN¥204.60 Million | ▲ +98.9% |
| 2014 | -3.02x | CN¥-218.41 Million | CN¥72.24 Million | CN¥290.65 Million | ▼ -3627.3% |
| 2013 | -0.08x | CN¥-23.49 Million | CN¥289.62 Million | CN¥313.11 Million | ▼ -177.1% |
| 2012 | 0.11x | CN¥26.38 Million | CN¥250.72 Million | CN¥224.35 Million | ▲ +145.2% |
| 2011 | -0.23x | CN¥-31.36 Million | CN¥134.58 Million | CN¥165.94 Million | ▼ -137.2% |
| 2010 | 0.63x | CN¥116.87 Million | CN¥186.55 Million | CN¥69.69 Million | ▼ -31.2% |
| 2009 | 0.91x | CN¥178.55 Million | CN¥196.14 Million | CN¥17.60 Million | ▲ +86.7% |
| 2008 | 0.49x | CN¥61.73 Million | CN¥126.59 Million | CN¥64.86 Million | ▼ -47.0% |
| 2007 | 0.92x | CN¥161.02 Million | CN¥174.94 Million | CN¥13.92 Million | — |